$-0.41 EPS Expected for Advaxis, Inc. (ADXS) as of June, 5

May 17, 2018 - By Cynthia Ashman

Advaxis, Inc. (NASDAQ:ADXS) Corporate Logo
Big Money Sentiment decreased to 1.12 in 2017 Q4. It has change of 0.11, from 2017Q3’s 1.23. The ratio fall due to Advaxis, Inc. positioning: 17 sold and 17 reduced. 16 funds amassed stakes and 22 increased stakes. Investors holded 16.94 million in 2017Q3 but now own 15.17 million shares or 10.45% less.
Bnp Paribas Arbitrage Sa has 8,156 shs for 0% of their capital. Adage Capital Prtn Gp Ltd Liability owns 4.00M shs for 0.03% of their capital. Barclays Plc reported 0% of its capital in Advaxis, Inc. (NASDAQ:ADXS). Amer Intl Grp Inc reported 0% of its capital in Advaxis, Inc. (NASDAQ:ADXS). Victory Cap Management owns 5,316 shs. Blackrock invested 0% of its capital in Advaxis, Inc. (NASDAQ:ADXS). Amer Century invested in 18,211 shs or 0% of the stock. Credit Suisse Ag invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Jefferies Group Ltd Liability Corp accumulated 442,900 shs. Voya Ltd Co holds 17,612 shs or 0% of its capital. 282,545 are held by Geode Mgmt Limited Liability Company. Parallax Volatility Advisers Ltd Partnership accumulated 5,502 shs. 12,317 were accumulated by Zacks Mgmt. Ontario – Canada-based Manufacturers Life Insur Communication The has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Alliancebernstein Ltd Partnership holds 75,300 shs or 0% of its capital.

Advaxis, Inc. registered $20,259 net activity with 0 insider purchases and 3 insider sales since December 29, 2017. On Friday, December 29 Bonstein Sara also sold $16,612 worth of Advaxis, Inc. (NASDAQ:ADXS). On Thursday, March 29 2,193 shs were sold by PETIT ROBERT, worth $3,553.

Advaxis, Inc. (NASDAQ:ADXS) is expected to announce earnings on June, 5., according to Faxor. Analysts forecast $-0.41 earnings per share. That’s $0.10 up or 19.61 % from 2017’s earnings of $-0.51. Wall Street now predicts -16.33 % EPS growth despite Advaxis, Inc. last quarter’s EPS of $-0.49. Ticker’s shares touched $1.87 during the last trading session after 6.50% change.Currently Advaxis, Inc. is downtrending after 77.70% change in last May 17, 2017. ADXS has also 753,197 shares volume. ADXS underperformed by 89.25% the S&P500.

Advaxis, Inc. (NASDAQ:ADXS) Ratings Coverage

In total 2 analysts cover Advaxis (NASDAQ:ADXS). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:ADXS) has 100% bullish analysts. 3 are the (NASDAQ:ADXS)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Wednesday, December 27 the company was maintained by H.C. Wainwright. In Tuesday, March 13 report Cantor Fitzgerald maintained it with “Overweight” rating and $5 target. On Wednesday, March 14 H.C. Wainwright maintained Advaxis, Inc. (NASDAQ:ADXS) with “Buy” rating.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States.The firm is valued at $97.83 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer.Currently it has negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

Another two news for Advaxis, Inc. (NASDAQ:ADXS) were briefly posted by: Nasdaq.com on May 14, 2018 with title “Analysis: Positioning to Benefit within Advaxis, elf Beauty, Heron Therapeutics, PVH, Energy Recovery, and AO Smith …”. The other Streetinsider.com‘s article was titled “Advaxis (ADXS) Says Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy” and posted on May 11, 2018.

Advaxis, Inc. (NASDAQ:ADXS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: